MedPath

A phase II trial of combination therapy of gemcitabine and hyperthermia in unresectable gallbladder cancer.

Phase 2
Conditions
unresectable gallbladder cancer
Registration Number
JPRN-UMIN000002824
Lead Sponsor
Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

Exclusion criteria in this study are as follows: 1. Interstitial pneumonitis, pulmonary fibrosis with radiological findings 2.Presence of uncontrolled diabetes, severe liver dysfunction, unstable angina, myocardial infarction within three months. 3.Presence of active severe infection 4.Pregnant, lactating women or women with suspected pregnancy. 5.Medical history of severe hypersensitivity. 6.Severe complications 7.Inappropriate patients for this study judged by the physicians.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
response rate
Secondary Outcome Measures
NameTimeMethod
survival time, progression-free survival time, safety, performance status
© Copyright 2025. All Rights Reserved by MedPath